

Implementation of Clinical Pharmacy Services in a Pediatric Dialysis Unit

A Thesis Submitted for Fulfillment of Master Degree in
Pharmaceutical Sciences (Clinical pharmacy)
Submitted to Faculty of Pharmacy, Ain Shams University

By

Radwa Maher Abd-el-Kader-el- Borolossy

B. Pharm. Sci
Demonstrator at Clinical Pharmacy Department
Faculty of Pharmacy
Ain Shams University

Under Supervision of

Prof. Dr. Osama A. Badary

Professor and Head of Clinical
Pharmacy Department
Faculty of Pharmacy
Ain Shams University

Prof. Dr. Ihab Zaki El-Hakim

Professor of Pediatrics
Faculty of Medicine
Ain Shams University

Dr. Lamiaa El- Wakeel

Lecturer of Clinical Pharmacy
Faculty of Pharmacy
Ain Shams University

Faculty of Pharmacy

Ain Shams University

2013

Acknowledgements

I am deeply thankful to “**GOD**” by the grace of whom, this work was possible.

I am greatly indebted to **Prof. Dr. Osama A. Badary**, Professor of Clinical Pharmacy, Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, for his kind supervision, direction, encouragement, and scientific support to make this work appear in its form.

I wish to express my deepest thanks and gratitude to **Prof. Dr. Ihab Zaki El-Hakim**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his guidance, useful remarks, and technical assistance during preparation of this work.

I wish also to express my deepest gratitude to **Dr. Lamiaa El- Wakeel**, Lecturer of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, for her kind guidance, encouragement, and revision of all scientific material in this work.

I am also grateful to all **members of the Department of Clinical Pharmacy**, Faculty of Pharmacy, Ain Shams University for their kind help.

Finally, I wish to thank all members of **My Family** for their continuous help, encouragement, and support.

Bgdwa Maher

List of contents

Contents	Page
List of abbreviations	iii
List of tables	v
List of figures	vii
Abstract	ix
Review of literature	
Renal insufficiency	
I- Definitions	1
II- Staging of CKD	3
III- Etiology	4
IV- Epidemiology	5
V- Pathophysiology	6
VI- Clinical presentation	7
VII- Complications	8
VIII- Management	17
Clinical pharmacy services in ESRD	
I. Clinical pharmacy	27
II. Role of the clinical pharmacist	27
III. Pharmaceutical care practice	28
IV. Principles of practice for pharmaceutical care	29
V. Impact of pharmaceutical care	35
VI. Drug Therapy Related Problems	35
VII. Risk factors for DTRPs in ESRD patients	40
Aim of the work	43
Patients and methods	44
Results	56
Discussion	91
Summary	100
References	105
Appendix	113

List of abbreviations

ACCP	American College of Clinical Pharmacy
ADR	Adverse Drug Reaction
ARF	Acute Renal Failure
AVF	Arterial Venous Fistula
BUN	Blood Urea Nitrogen
Ca*P	Calcium- Phosphorus Product
CAPD	Continuous Ambulatory Peritoneal Dialysis
CCPD	Continuous Cyclic Peritoneal Dialysis
CKD	Chronic Kidney Disease
CRF	Chronic Renal Failure
DI	Drug Interaction
DTRs	Drug Therapy Related Problems
DWI	Drug use Without Indication
ESRD	End Stage Renal Disease
GFR	Glomerular Filtration Rate
GH	Growth Hormone
GN	Glomerulonephritis
HD	Hemodialysis
IDS	Improper Drug Selection
IGF-1	Insulin like Growth Factor-1
IPD	Intermittent Peritoneal Dialysis
IWD	Indication Without Drug Therapy
KDOQI	Kidney Disease Outcomes Quality Initiative
LVH	Left ventricular hypertrophy
NKF	National Kidney Foundation
OD	Over-Dosage
PCP	Pharmaceutical Care Plan
PD	Peritoneal Dialysis
PILs	Patient Information Leaflets
pmp	per million populations
PTH	Parathyroid Hormone
QoL	Quality of Life

rhuEPO	Recombinant Human Erythropoietin
rhGH	Recombinant Human Growth Hormone
RTSQ	Renal Treatment Satisfaction Questionnaire
UD	Sub-Therapeutic Dosage
USRDS	United State Renal Data System
VUR	Vesicouretric Reflux

List of tables

Table	Page
Table (1): Normal GFR in children and adolescents.	2
Table (2): Stages of Chronic Kidney Disease.	4
Table (3): Etiology of CRF in a group of Egyptian children.	5
Table (4): Description of Drug Therapy Problem Categories.	36
Table (5): The Renal Treatment Satisfaction Questionnaire.	51
Table (6): Baseline Demographics for test & control groups.	57
Table (7): Baseline Clinical Characteristics of test & control groups.	58
Table (8): Baseline Medications administered by test & control groups.	62
Table (9): Baseline blood pressure measurement in test & control groups.	63
Table (10): Baseline laboratory data in test & control groups.	64
Table (11): Baseline Median total score of the RTSQ in test & control groups.	65
Table (12): Baseline RTSQ individual question's score in test & control groups.	66
Table (13): Drug Therapy related problems in test group and the percentage of interventions being accepted and implemented.	70
Table (14): Systolic blood pressure measurement in control & test groups at baseline & at the end of the study.	73
Table (15): Diastolic blood pressure measurement in control & test groups at baseline & at the end of the study.	75
Table (16): Serum calcium levels in control & test groups at baseline & at the end of the study.	77
Table (17): Median serum phosphorus level in control & test groups at baseline & at the end of the study	79
Table (18): Median serum PTH level in control, test groups at baseline & at the end of the study.	82
Table (19): Median serum Ca*P product in control, test groups at	84

baseline & at the end of the study.	
Table (21): Median total score of the RTSQ in control and test group at baseline and at end of the study.	87
Table (22): RTSQ individual question's score in the control and test group at end of the study	88

List of figures

Figure	Page
Figure (1): Etiology of growth retardation in children.	10
Figure (2): Pathophysiology of Increased Cardiovascular Risk in End-Stage Renal Disease.	14
Figure (3): Difference between concentric and eccentric left ventricular hypertrophy.	16
Figure(4): Patterns of Solute Removal with Hemodialysis	21
Figure (5): Creation of arterial-venous fistula.	22
Figure (6): Process of Pharmaceutical care practice.	34
Figure (7): categories of drug therapy problems.	36
Figure (8): Frequency distribution of medication-related problems in ambulatory hemodialysis patients.	42
Figure (9): Schematic representation of the study design and patient allocation.	45
Figure (10): Recommendation form.	53
Figure (11): Patient information leaflet.	54
Figure (12): Medication chart for each patient.	55
Figure (13): Percentages of the causes of ESRD in the test group.	59
Figure (14): Percentages of the causes of ESRD in the control group.	59
Figure (15): Percentages of comorbidities in the test group.	60
Figure (16): Percentages of comorbidities in the control group.	60
Figure (17): Percentages of drug therapy related problems in the test group.	69
Figure (18): Median systolic blood pressure in the control group & test groups at baseline & at the end of the study.	74
Figure (19): Median diastolic blood pressure in the control group & test groups at baseline & at the end of the study.	76
Figure (20): Median serum calcium levels in the control group & test groups at baseline & at the end of the study.	78

Figure (21): Median serum Phosphorus levels in the control group & test groups at baseline & at the end of the study.	80
Figure (22): Median serum Parathyroid Hormone levels in the control group & test groups at baseline & at the end of the study.	83
Figure (23): Median serum Calcium-Phosphorus Product levels in the control group & test groups at baseline & at the end of the study.	85
Figure (24): Median total score of RTSQ in the control group & test groups at baseline & at the end of the study.	90

Abstract

Introduction:

Chronic kidney disease (CKD) in children is a major public health problem that refers to a condition related to irreversible kidney damage that can further progress to end-stage renal disease (ESRD). When disease progresses to a stage where kidney failure occurs, patients are required to start renal replacement therapies, either through dialysis or transplantation. ESRD patients who are on hemodialysis (HD) have complex drug regimens and receive nearly 10 to 12 medications daily, many of which requires multiple doses/day. Due to poly pharmacy, frequent medication adjustments on dialysis versus non- dialysis days, medically unstable nature of the disease and restricted life styles, these patients are at high risk for developing drug therapy related problems (DTRPs). Identification and resolution of DTRPs can occur through presence of clinical pharmacist as a member of multidisciplinary care CKD team via the provision of pharmaceutical care.

Aim of the work:

The current study was designed to detect drug therapy related problems in children undergoing hemodialysis and to assess and evaluate the impact of clinical pharmacist interventions on the clinical outcome of children undergoing hemodialysis.

Patients and Methods:

A group of 50 patients, underwent hemodialysis were divided into 2 groups each of 25 patients, the control group received the usual care by the physicians, while the test group received the pharmaceutical care by the clinical pharmacist in addition to the usual care over a nine months period. The outcome the pharmaceutical care plan implemented by the clinical pharmacist was assessed by estimation of several parameters including: {measurement of blood pressure, serum calcium level, serum phosphorus level, serum PTH level, serum calcium-phosphorus product level and using renal treatment satisfaction questionnaire (RTSQ)} that were assessed at baseline (prior to intervention) and at end of study (after intervention).

Results:

The results of the current study have showed that there was a highly significant decrease in both mean systolic and diastolic blood pressure in the test group and a highly significant decrease in median serum phosphorus level, median serum Ca*P product level, median serum PTH level in the test group and there was a significant increase in median serum calcium level in the test group as compared to their baseline values. There was a highly significant difference between the test and control group in both the individual score of each question of the RTSQ and the total score of the 11 items of the RTSQ.

Conclusion:

The clinical pharmacist is of paramount importance to be present as a member of the healthcare team taking care of ambulatory HD patients to provide pharmaceutical care services to resolve DTRPs and hence, improve overall patient care.

Key words:

End stage renal disease – Hemodialysis – Poly pharmacy – Drug therapy related problems – Pharmaceutical care plan.

Aim of the Work

The main aim of the study is to detect drug therapy related problems in children undergoing hemodialysis.

In addition to assessment and evaluation of the impact of clinical pharmacist interventions on the clinical outcome of children undergoing hemodialysis.

Part 1: Renal insufficiency

I. Definitions

Impairment of normal kidney function is referred as renal insufficiency or renal failure, based on the time course of development, renal failure has been historically divided into 2 broad categories: acute renal failure and chronic renal failure. **(Schonder, 2010)**

1-Acute renal failure (ARF) is a clinical syndrome in which a sudden (hours to weeks) deterioration in renal function results in the inability of the kidneys to maintain fluid and electrolyte homeostasis, the loss of renal function is reversible in the majority of cases.

The overall incidence of ARF in pediatrics is 0.8 per 100,000 total population, while the incidence of ARF in neonates ranged from 8% to 24% of newborns. **(Andreoli, 2009)**

Fifty to seventy five percent of ARF patients require dialysis to compensate loss of kidney function. **(Vogt and Avner, 2007)**

The three leading causes of acute renal failure in children in developing countries are: hemolytic uremic syndrome (31%), glomerulonephritis (23%), postoperative sepsis and pre-renal ischemia (18%). **(Chan et al, 2002)**

2-Chronic renal failure (CRF) is defined as gradual and usually permanent (irreversible) loss of kidney function over months to years, and is characterized by gradual replacement of normal kidney architecture with interstitial fibrosis.

(National kidney foundation, 2008a; Matzke, 2011)

The progression of renal malfunction towards end stage renal failure is common among patients with CRF irrespective of the underlying kidney disorder. **(Phan et al, 2008)**

3-End- stage renal disease (ESRD) refers to a stage of chronic kidney disease where there is total or near total loss of kidney function and most individuals in this stage of kidney disease need dialysis or transplantation to stay alive. ESRD is one of the main health problems in Egypt. **(Broscious and Castagnola, 2006; Allam et al, 2010)**

Chronic Kidney disease (CKD):

The National Kidney Foundation (NKF) and the Kidney Disease Outcomes Quality Initiative (KDOQI) workgroup defined CKD as either:

A- Kidney damage for 3 months or longer, as defined by structural or functional abnormalities of the kidney, manifested by either: pathological abnormalities, or markers of kidney damage abnormalities in the composition of blood or urine, or abnormalities in imaging tests.

B- Glomerular filtration rate (GFR) $< 60 \text{ ml/min/1.73m}^2$ for 3 months or longer, with or without kidney damage. (**National Kidney Foundation, 2008a**)

This definition is not applicable to children younger than 2 years because they normally have a low GFR, even when corrected for body surface area.

GFR is equal to the sum of the filtration rates in all of the functioning nephrons and therefore, can give an estimate of renal function. Interpretation requires a clear understanding that GFR varies according to age, gender, and body size. The normal GFR is much lower in infancy and reaches adult values after one year of age. Despite this, a calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect renal impairment even in toddlers and infants with CKD. (Table 1) shows the normal GFR in children and adolescents.

Table (1): Normal GFR in children and adolescents

Age	Mean GFR \pm SD (ml/min/1.73m ²)
1 week (males & females)	41 \pm 15
2 week (males & females)	66 \pm 25
>8 week (males & females)	96 \pm 22
2-12 years (males & females)	133 \pm 27
13-21 years (males)	140 \pm 30
13-21 years (females)	126 \pm 22

(**Jayaranan and Vander voort, 2010**)

II. Staging of CKD:

The KDOQI has developed a classification system for the severity of CKD based on GFR and independent of primary renal diagnosis (Table 2). (**National Kidney Foundation, 2008a**)

Stage (1): Kidney damage with normal or increased GFR ($> 90 \text{ ml/min/1.73m}^2$)

This stage is defined by the presence of structural or functional abnormalities of the kidney, initially without decreased GFR which over time can lead to decreased GFR.

Stage (2): Mild reduction in GFR (60 to 89 ml/min/1.73 m²)

At this stage, patients usually have hypertension and may have laboratory abnormalities indicative of dysfunction in other organ systems, but most patients are asymptomatic.

Stage (3): Moderate reduction in GFR (30 to 59 ml/min/1.73 m²)

This stage is characterized primarily by the presence of azotemia, defined by the accumulation of the end products of nitrogen metabolism in the blood and expressed by an elevation in serum creatinine and blood urea nitrogen (BUN) concentrations. Erythropoietin production decrease and laboratory abnormalities reflecting dysfunction in other organ systems are usually present. Although patients may have symptoms, they often remain remarkably asymptomatic even though their kidney function may be reduced as much as 70 %.

Stage (4): Severe reduction in GFR (15 to 29 ml/min/1.73 m²):

In this severe stage of CKD, the worsening of azotemia, anemia and other laboratory abnormalities reflect dysfunction in several organ systems. However, patients usually have mild symptoms.

Stage (5): Kidney failure GFR $< 15 \text{ ml/min/1.73 m}^2$:

In most cases, this level of kidney function is accompanied by a constellation of symptoms and laboratory abnormalities of several organ systems, which are collectively referred to as uremia. Initiation of kidney replacement therapy (dialysis or transplantation) is typically required for treatment, of co-morbid conditions or